Acquires 25% stake in Cannasoul Analytics for up to $4 million to support R&D for cannabinoid- and psilocybin mushroom-based therapeutics for multiple indicationsPartners to drive development and commercialization of Cannasoul Analytics' intellectual property and technologies licensed from The Technion - Israel Institute of TechnologyNEW YORK, Nov.

收购Cannasoul Analytics 25%的股份，价值高达400万美元，用于支持基于多种适应症的基于大麻素和psilocybin蘑菇的疗法的研发，以推动Cannasoul Analytics的知识产权和技术的开发和商业化，该技术获得以色列理工学院许可纽约，11月。

2, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ('Synaptogenix' or the 'Company'), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced a new partnership with Cannasoul Analytics Ltd. ('Cannasoul') in support of research and development of pharmaceutical therapeutics.

22023/PRNewswire/-Synaptogenix，Inc。（纳斯达克股票代码：SNPX）（'Synaptogenix'或'公司'），一家新兴的开发神经退行性疾病治疗药物的生物制药公司，今天宣布与Cannasoul Analytics Ltd.建立新的合作关系。（'Cannasoul'）支持药物治疗的研究和开发。

Cannasoul is founded by the Technion Research & Development Foundation ('TRDF'), the commercialization arm of The Technion – Israel Institute of Technology ('The Technion'), and world-renowned cannabis key opinion leader and researcher Professor Dedi Meiri from The Technion..

Cannasoul由Technion研发基金会（'TRDF'），Technion-以色列理工学院（'the Technion'）的商业部门以及世界知名的大麻主要意见领袖和研究员Dedi Meiri教授创立。技术。。

Continue Reading

继续阅读

Dr. Dedi Meiri Head of the Laboratory of Cancer Biology and Cannabinoid Research, Technion Founder, Cannasoul Ltd.

Dedi Meiri博士Cannasoul Ltd.Technion创始人癌症生物学和大麻素研究实验室负责人。

Professor Meiri heads the Laboratory of Cancer Biology and Cannabinoid Research at The Technion's Faculty of Biology. Professor Meiri and The Technion founded Cannasoul in 2018 for the development of cannabinoid-based and other therapeutics for various indications and vertical markets. Cannasoul has developed technology in large disease markets including leukemia ($12.7B by 20281), epilepsy ($14.7B by 20332), and sleep disorders ($73.5B by 20323).

Meiri教授领导Technion生物学院癌症生物学和大麻素研究实验室。Meiri教授和Technion于2018年创立了Cannasoul，为各种适应症和垂直市场开发基于大麻素和其他疗法。Cannasoul在大型疾病市场开发了技术，包括白血病（到20281年为12.7亿美元），癫痫症（到20332年为14.7亿美元）和睡眠障碍（到20323年为73.5亿美元）。

Under terms of the investment agreement, Synaptogenix obtains a preemptive right to fund the further research and commercialization of certain intellectual property, technology, and future products developed by Cannasoul and licensed from The Technion..

根据投资协议条款，Synaptogenix获得先发制人的权利，以资助Cannasoul开发并从Technion许可的某些知识产权，技术和未来产品的进一步研究和商业化。。

'Cannasoul is pleased to welcome Synaptogenix as a key partner in our development of groundbreaking therapeutics derived from natural compounds. We appreciate the strong support and confidence in our laboratory's high standards and pioneering scientific approach that this investment represents. Together with Synaptogenix, we look forward to advancing our leadership in developing effective cannabis and psilocybin-based treatments that will be easily accessible to patients worldwide,' stated Professor Peretz Lavie, 16th President of the Technion and Cannasoul Board Member..

“Cannasoul很高兴欢迎Synaptogenix成为我们开发天然化合物突破性疗法的关键合作伙伴。我们感谢我们实验室对这项投资所代表的高标准和开创性科学方法的大力支持和信心。Technion和Cannasoul董事会第16任总裁Peretz Lavie教授说，与Synaptogenix一起，我们期待在开发有效的大麻和基于裸盖菇素的治疗方法方面发挥领导作用。。

'On behalf of Cannasoul, we are very excited to partner with Synaptogenix and believe that Synaptogenix's expertise in pharmaceutical development will enable us to advance development and commercialization of Cannasoul's current intellectual property and engage in new projects based on the exciting research being conducted in my lab at The Technion,' added Dr.

“代表Cannasoul，我们非常高兴与Synaptogenix合作，相信Synaptogenix在药物开发方面的专业知识将使我们能够促进Cannasoul当前知识产权的开发和商业化，并基于我实验室进行的令人兴奋的研究参与新项目。在Technion，“博士补充说。

Meiri.'Synaptogenix is excited to gain access to Cannasoul's intellectual property licensed from the prestigious Technion Institute of Technology, which is consistently ranked among the world's leading science and technology universities,' stated Dr. Alan Tuchman, Chief Executive Officer of Synaptogenix.Synaptogenix is well-funded with approximately $33 million in cash as of June 30, 2023.

梅里。'Synaptogenix的首席执行官Alan Tuchman博士说，Synaptogenix很高兴能够获得由着名的Technion理工学院许可的Cannasoul知识产权，该技术一直位居世界领先的科技大学之列.Synaptogenix资金充足截至2023年6月30日，现金约为3300万美元。

Based on this strong financial position, the Company's stated business strategy includes potential acquisitions of asset rights or funding for research on other assets. The investment in Cannasoul embodies this strategy.Founded in 1912, The Technion is Israel's largest center of applied research and a major source of innovation driving the Israeli economy.

基于这种强大的财务状况，公司所述的商业战略包括潜在收购资产权利或用于研究其他资产的资金。对Cannasoul的投资体现了这一战略。Technion成立于1912年，是以色列最大的应用研究中心，也是推动以色列经济的主要创新来源。

The Technion is ranked among the leading technological universities worldwide and ties the Massachusetts Institute of Technology (MIT) for the number of Nobel Prize laureates this century.About SynaptogenixSynaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases.

该技术被评为全球领先的技术大学之一，并将麻省理工学院（MIT）与本世纪诺贝尔奖获得者的数量联系起来。关于SynaptogenixSynaptogenix是一家临床阶段的生物制药公司，历来致力于开发神经退行性疾病的新疗法。

Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis.

Synaptogenix已对其阿尔茨海默病的主要治疗候选药物苔藓抑素-1进行了临床和临床前研究。临床前研究还证明了苔藓抑素对罕见疾病脆性X综合征和其他神经退行性疾病如多发性硬化症的再生作用机制。